{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-25-000024","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.447310+00:00","generated_at":"2026-05-23T01:55:26.324299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63","bullets":["Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).","Tyvaso family revenue $466.3M (+25% YoY), with Tyvaso DPI up 33% to $302.5M and nebulized Tyvaso up 13% to $163.8M.","R&D expense $149.0M (+43% YoY) driven by $30.0M milestone payments for drug delivery device technologies and adjustments to contingent consideration.","Upcoming catalysts: TETON 2 readout in IPF, UKidney first-in-human study; IND filings planned for UHeart and UThymoKidney."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-25-000024","json":"https://secwatch.observer/filing/0001082554-25-000024.json","markdown":"https://secwatch.observer/filing/0001082554-25-000024.md","text":"https://secwatch.observer/filing/0001082554-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/0001082554-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/uthr-20250430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:55:26.324299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}